Viscoleo
Viscoleo is a thin or low-viscosity vegetable oil.[1] It is specifically a proprietary form of fractionated coconut oil and a medium-chain triglyceride (MCT) oil.[1][2] It is prepared from the dried, solid endosperm of the fruit Cocos nucifera (coconut tree) via hydrolysis, fractionation, and purification.[3] Viscoleo is composed of the medium-chain fatty acids caprylic acid (C8) (55â60%), capric acid (C10) (40%), lauric acid (C12) (1â5%), and caproic acid (C6) (0.5%).[4][5][3][6][7] It is used as an oil vehicle for several depot antipsychotics including clopentixol decanoate, flupentixol decanoate, pipotiazine palmitate, zuclopentixol acetate, and zuclopentixol decanoate.[1][8] Injectable antipsychotics using Viscoleo as a carrier may be absorbed more rapidly and have shorter durations than preparations using sesame oil.[8][9]
| Medication | Brand name | Class | Vehicle | Dosage | Tmax | t1/2 single | t1/2 multiple | logPc | Ref |
|---|---|---|---|---|---|---|---|---|---|
| Aripiprazole lauroxil | Aristada | Atypical | Watera | 441â1064Â mg/4â8Â weeks | 24â35Â days | ? | 54â57Â days | 7.9â10.0 | |
| Aripiprazole monohydrate | Abilify Maintena | Atypical | Watera | 300â400Â mg/4Â weeks | 7Â days | ? | 30â47Â days | 4.9â5.2 | |
| Bromperidol decanoate | Impromen Decanoas | Typical | Sesame oil | 40â300Â mg/4Â weeks | 3â9Â days | ? | 21â25Â days | 7.9 | [10] |
| Clopentixol decanoate | Sordinol Depot | Typical | Viscoleob | 50â600Â mg/1â4Â weeks | 4â7Â days | ? | 19Â days | 9.0 | [11] |
| Flupentixol decanoate | Depixol | Typical | Viscoleob | 10â200Â mg/2â4Â weeks | 4â10Â days | 8Â days | 17Â days | 7.2â9.2 | [11][12] |
| Fluphenazine decanoate | Prolixin Decanoate | Typical | Sesame oil | 12.5â100Â mg/2â5Â weeks | 1â2Â days | 1â10Â days | 14â100Â days | 7.2â9.0 | [13][14][15] |
| Fluphenazine enanthate | Prolixin Enanthate | Typical | Sesame oil | 12.5â100Â mg/1â4Â weeks | 2â3Â days | 4Â days | ? | 6.4â7.4 | [14] |
| Fluspirilene | Imap, Redeptin | Typical | Watera | 2â12Â mg/1Â week | 1â8Â days | 7Â days | ? | 5.2â5.8 | [16] |
| Haloperidol decanoate | Haldol Decanoate | Typical | Sesame oil | 20â400Â mg/2â4Â weeks | 3â9Â days | 18â21Â days | 7.2â7.9 | [17][18] | |
| Olanzapine pamoate | Zyprexa Relprevv | Atypical | Watera | 150â405Â mg/2â4Â weeks | 7Â days | ? | 30Â days | â | |
| Oxyprothepin decanoate | Meclopin | Typical | ? | ? | ? | ? | ? | 8.5â8.7 | |
| Paliperidone palmitate | Invega Sustenna | Atypical | Watera | 39â819Â mg/4â12Â weeks | 13â33Â days | 25â139Â days | ? | 8.1â10.1 | |
| Perphenazine decanoate | Trilafon Dekanoat | Typical | Sesame oil | 50â200Â mg/2â4Â weeks | ? | ? | 27Â days | 8.9 | |
| Perphenazine enanthate | Trilafon Enanthate | Typical | Sesame oil | 25â200Â mg/2Â weeks | 2â3Â days | ? | 4â7Â days | 6.4â7.2 | [19] |
| Pipotiazine palmitate | Piportil Longum | Typical | Viscoleob | 25â400Â mg/4Â weeks | 9â10Â days | ? | 14â21Â days | 8.5â11.6 | [12] |
| Pipotiazine undecylenate | Piportil Medium | Typical | Sesame oil | 100â200Â mg/2Â weeks | ? | ? | ? | 8.4 | |
| Risperidone | Risperdal Consta | Atypical | Microspheres | 12.5â75Â mg/2Â weeks | 21Â days | ? | 3â6Â days | â | |
| Zuclopentixol acetate | Clopixol Acuphase | Typical | Viscoleob | 50â200Â mg/1â3Â days | 1â2Â days | 1â2 days | 4.7â4.9 | ||
| Zuclopentixol decanoate | Clopixol Depot | Typical | Viscoleob | 50â800Â mg/2â4Â weeks | 4â9Â days | ? | 11â21Â days | 7.5â9.0 | |
| Note: All by intramuscular injection. Footnotes: a = Microcrystalline or nanocrystalline aqueous suspension. b = Low-viscosity vegetable oil (specifically fractionated coconut oil with medium-chain triglycerides). c = Predicted, from PubChem and DrugBank. Sources: Main: See template. | |||||||||
References
[edit]- 1 2 3 De Risio A, Lang AP (February 2014). "History and therapeutic rationale of long acting antipsychotics". Curr Clin Pharmacol. 9 (1): 39â52. doi:10.2174/15748847113089990057. PMIDÂ 23343446.
- â Larsen, Susan W.; Thing, Mette A.; Larsen, Claus (2012). "Oily (Lipophilic) Solutions and Suspensions". Long Acting Injections and Implants. pp. 113â135. doi:10.1007/978-1-4614-0554-2_7. ISBN 978-1-4614-0553-5.
- 1 2 Kai A. R. Rönnholm (1986). Human Milk Feeding in Very Low-birth-weight Infants: A Study of Protein Requirement, as Estimated from Growth, Serum Protein, Amino Acid and Hemoglobin Concentrations, and Riboflavin Status During the Early Postnatal Weeks. Painovalssi. p. 23. ISBN 978-951-99786-8-0.
MCT oil (Viscoleo, obtained from Adopan, Kastrup, Denmark) is prepared from dried, solid endosperm of the fruit of Cocos nucifera by hydrolysis, fractionation, and purification. It consists of a mixture of triglycerides containing only short- and medium-chain saturated fatty acids, mainly as octanoic and decanoic acids.
- â Svendsen O, Aaes-JĂžrgensen T (November 1979). "Studies on the fate of vegetable oil after intramuscular injection into experimental animals". Acta Pharmacol Toxicol (Copenh). 45 (5): 352â78. doi:10.1111/j.1600-0773.1979.tb02404.x. PMIDÂ 539434.
Viscoleo is a thin vegetable oil of triglycerides containing only short chain saturated fatty acids, caprylic acid (55%), capric acid (40%) and lauric acid (5%).
- â Svendsen O (April 1983). "Local muscle damage and oily vehicles: a study on local reactions in rabbits after intramuscular injection of neuroleptic drugs in aqueous or oily vehicles". Acta Pharmacol Toxicol (Copenh). 52 (4): 298â304. doi:10.1111/j.1600-0773.1983.tb01104.x. PMIDÂ 6135293.
Viscoleo@ and sesame oil are triglyceride vegetable oils. The triglycerides in Viscoleo@ contain short chain and saturated fatty acids, caprylic acid, capric acid and lauric acid, [...]
- â Radha Raman Gupta (1988). Phenothiazines and 1,4-benzothiazines: Chemical and Biomedical Aspects. Elsevier. p. 688. ISBN 978-0-444-42967-4.
ViscoleoÂź is a triglyceride vegetable oil containing short-chain saturated fatty acids as well as caprylic acid, capric acid, and lauric acid.
- â Larsen SW, Rinvar E, Svendsen O, Lykkesfeldt J, Friis GJ, Larsen C (November 2001). "Determination of the disappearance rate of iodine-125 labelled oils from the injection site after intramuscular and subcutaneous administration to pigs". Int J Pharm. 230 (1â2): 67â75. doi:10.1016/s0378-5173(01)00860-2. PMIDÂ 11672957.
- 1 2 Spanarello S, La Ferla T (2014). "The pharmacokinetics of long-acting antipsychotic medications". Curr Clin Pharmacol. 9 (3): 310â7. doi:10.2174/15748847113089990051. PMIDÂ 23343447.
- â Remington GJ, Adams ME (April 1995). "Depot neuroleptic therapy: clinical considerations". Can J Psychiatry. 40 (3 Suppl 1): S5â11. doi:10.1177/070674379504003S02. PMIDÂ 7627927. S2CIDÂ 151908598.
- â Parent M, Toussaint C, Gilson H (1983). "Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation". Current Therapeutic Research. 34 (1): 1â6.
- 1 2 JĂžrgensen A, OverĂž KF (1980). "Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels". Acta Psychiatrica Scandinavica. Supplementum. 279: 41â54. doi:10.1111/j.1600-0447.1980.tb07082.x. PMIDÂ 6931472.
- 1 2 Reynolds JE (1993). "Anxiolytic sedatives, hypnotics and neuroleptics.". Martindale: The Extra Pharmacopoeia (30th ed.). London: Pharmaceutical Press. pp. 364â623.
- â Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR (May 1984). "Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches". The Journal of Clinical Psychiatry. 45 (5 Pt 2): 50â9. PMIDÂ 6143748.
- 1 2 Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979). "Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man". British Journal of Clinical Pharmacology. 7 (4): 325â31. doi:10.1111/j.1365-2125.1979.tb00941.x. PMCÂ 1429660. PMIDÂ 444352.
- â Young D, Ereshefsky L, Saklad SR, Jann MW, Garcia N (1984). Explaining the pharmacokinetics of fluphenazine through computer simulations. (Abstract.). 19th Annual Midyear Clinical Meeting of the American Society of Hospital Pharmacists. Dallas, Texas.
- â Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM, Marsboom RH, HĂ©rin VV, Schaper WK (November 1970). "The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug". Arzneimittel-Forschung. 20 (11): 1689â98. PMID 4992598.
- â Beresford R, Ward A (January 1987). "Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis". Drugs. 33 (1): 31â49. doi:10.2165/00003495-198733010-00002. PMIDÂ 3545764.
- â Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ (1982). "Pharmacokinetics of haloperidol decanoate. A 2-year follow-up". International Pharmacopsychiatry. 17 (4): 238â46. doi:10.1159/000468580. PMIDÂ 7185768.
- â Larsson M, Axelsson R, Forsman A (1984). "On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate". Current Therapeutic Research. 36 (6): 1071â88. INISTÂ 8951670.